Nonalcoholic steatohepatitis is associated with a state of betaine-insufficiency

Liver International

Volumn 37, Issue 4, 2017, Pages 611-619

  Sookoian, Silvia ^a   Puri, Puneet ^b   Castaño, Gustavo O ^c   Scian, Romina ^a   Mirshahi, Faridodin ^b   Sanyal, Arun J ^b   Pirola, Carlos J ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Hospital General de Agudos Dr Abel Zubizarreta   (Argentina)

Author keywords

betaine; biomarkers; dimethylglycine dehydrogenase mitochondrial; DNA methylation; epigenetics; fibrosis; genetics; inflammation; metabolomics; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis

Indexed keywords

BETAINE; BIOLOGICAL MARKER; DIMETHYLGLYCINE DEHYDROGENASE; DMGDH PROTEIN, HUMAN; MITOCHONDRIAL PROTEIN;

ADULT; AMINO ACID DEFICIENCY; ARGENTINA; ARTICLE; BETAINE INSUFFICIENCY; CASE CONTROL STUDY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENETIC ANALYSIS; GENETIC ASSOCIATION; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LIVER BIOPSY; LIVER FIBROSIS; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; BLOOD; DISEASE EXACERBATION; FATTY LIVER; FIBROSIS; GENETICS; LIVER; MISSENSE MUTATION; PATHOLOGY; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX;

ADULT; ARGENTINA; BETAINE; BIOMARKERS; CASE-CONTROL STUDIES; DIMETHYLGLYCINE DEHYDROGENASE; DISEASE PROGRESSION; FATTY LIVER; FEMALE; FIBROSIS; HUMANS; LIVER; MALE; MIDDLE AGED; MITOCHONDRIAL PROTEINS; MUTATION, MISSENSE; NON-ALCOHOLIC FATTY LIVER DISEASE; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX;

EID: 84994853514     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13249     Document Type: Article

References (40)

1. Brunt EM. Histopathology of non-alcoholic fatty liver disease. Clin Liver Dis. 2009;13:533–544.
2. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313:2263–2273.
3. Satapathy SK, Sanyal AJ. Epidemiology and natural history of nonalcoholic fatty liver disease. Semin Liver Dis. 2015;35:221–235.
4. Sookoian S, Pirola CJ. The genetic epidemiology of nonalcoholic fatty liver disease: toward a personalized medicine. Clin Liver Dis. 2012;16:467–485.
5. Ahrens M, Ammerpohl O, von SW, et al. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab 2013;18:296–302.
6. Murphy SK, Yang H, Moylan CA, et al. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145:1076–1087.
7. Sookoian S, Rosselli MS, Gemma C, et al. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor gamma coactivator 1alpha promoter. Hepatology. 2010;52:1992–2000.
8. Zeybel M, Hardy T, Robinson SM, et al. Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease. Clin Epigenetics. 2015;7:25.
9. Pirola CJ, Gianotti TF, Burgueno AL, et al. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut. 2013;62:1356–1363.
10. Sookoian S, Pirola CJ. DNA methylation and hepatic insulin resistance and steatosis. Curr Opin Clin Nutr Metab Care. 2012;15:350–356.
11. Sookoian S, Pirola CJ. Epigenetics of insulin resistance: an emerging field in translational medicine. Curr Diab Rep. 2013;13:229–237.
12. Pacana T, Cazanave S, Verdianelli A, et al. Dysregulated hepatic methionine metabolism drives homocysteine elevation in diet-induced nonalcoholic fatty liver disease. PLoS One. 2015;10:e0136822.
13. Lu SC. S-Adenosylmethionine. Int J Biochem Cell Biol. 2000;32:391–395.
14. Obeid R. The metabolic burden of methyl donor deficiency with focus on the betaine homocysteine methyltransferase pathway. Nutrients. 2013;5:3481–3495.
15. Deminice R, da Silva RP, Lamarre SG, et al. Betaine supplementation prevents fatty liver induced by a high-fat diet: effects on one-carbon metabolism. Amino Acids. 2015;47:839–846.
16. Ji C, Shinohara M, Kuhlenkamp J, Chan C, Kaplowitz N. Mechanisms of protection by the betaine-homocysteine methyltransferase/betaine system in HepG2 cells and primary mouse hepatocytes. Hepatology. 2007;46:1586–1596.
17. Ji C, Shinohara M, Vance D, et al. Effect of transgenic extrahepatic expression of betaine-homocysteine methyltransferase on alcohol or homocysteine-induced fatty liver. Alcohol Clin Exp Res. 2008;32:1049–1058.
18. Zhu X, Song J, Mar MH, Edwards LJ, Zeisel SH. Phosphatidylethanolamine N-methyltransferase (PEMT) knockout mice have hepatic steatosis and abnormal hepatic choline metabolite concentrations despite ingesting a recommended dietary intake of choline. Biochem J. 2003;370(Pt 3):987–993.
19. Konstantinova SV, Tell GS, Vollset SE, et al. Divergent associations of plasma choline and betaine with components of metabolic syndrome in middle age and elderly men and women. J Nutr. 2008;138:914–920.
20. Detopoulou P, Panagiotakos DB, Antonopoulou S, Pitsavos C, Stefanadis C. Dietary choline and betaine intakes in relation to concentrations of inflammatory markers in healthy adults: the ATTICA study. Am J Clin Nutr. 2008;87:424–430.
21. Craig SA. Betaine in human nutrition. Am J Clin Nutr. 2004;80:539–549.
22. Shin SY, Fauman EB, Petersen AK, et al. An atlas of genetic influences on human blood metabolites. Nat Genet. 2014;46:543–550.
23. Kleiner DE, Brunt EM, Van NM, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.
24. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53:810–820.
25. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet. 2006;38:209–213.
26. Bergman RN, Stefanovski D, Buchanan TA, et al. A better index of body adiposity. Obesity. 2011;19:1083–1089.
27. Kwok R, Tse YK, Wong GL, et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease–the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2014;39:254–269.
28. Pirola CJ, Fernandez GT, Castano GO, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015;64:800–812.
29. Kawakami S, Han KH, Nakamura Y, et al. Effects of dietary supplementation with betaine on a nonalcoholic steatohepatitis (NASH) mouse model. J Nutr Sci Vitaminol. 2012;58:371–375.
30. Kwon dY, Jung YS, Kim SJ, et al. Impaired sulfur-amino acid metabolism and oxidative stress in nonalcoholic fatty liver are alleviated by betaine supplementation in rats. J Nutr 2009;139:63–68.
31. Wang LJ, Zhang HW, Zhou JY, et al. Betaine attenuates hepatic steatosis by reducing methylation of the MTTP promoter and elevating genomic methylation in mice fed a high-fat diet. J Nutr Biochem. 2014;25:329–336.
32. Xu L, Huang D, Hu Q, et al. Betaine alleviates hepatic lipid accumulation via enhancing hepatic lipid export and fatty acid oxidation in rats fed with a high-fat diet. Br J Nutr. 2015;113:1835–1843.
33. Zhang W, Wang LW, Wang LK, et al. Betaine protects against high-fat-diet-induced liver injury by inhibition of high-mobility group box 1 and Toll-like receptor 4 expression in rats. Dig Dis Sci. 2013;58:3198–3206.
34. Kathirvel E, Morgan K, Nandgiri G, et al. Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine. Am J Physiol Gastrointest Liver Physiol. 2010;299:G1068–G1077.
35. Abdelmalek MF, Sanderson SO, Angulo P, et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology. 2009;50:1818–1826.
36. He DH, Yang M, Zhang RH, et al. Dietary patterns associated metabolic syndrome in chinese adults. Biomed Environ Sci. 2015;28:370–373.
37. Chen YM, Liu Y, Zhou RF, et al. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. Sci Rep. 2016;6:19076.
38. Demirkan A, Henneman P, Verhoeven A, et al. Insight in genome-wide association of metabolite quantitative traits by exome sequence analyses. PLoS Genet. 2015;11:e1004835.
39. Song J, da Costa KA, Fischer LM, et al. Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD). FASEB J. 2005;19:1266–1271.
40. Lever M, Slow S. The clinical significance of betaine, an osmolyte with a key role in methyl group metabolism. Clin Biochem. 2010;43:732–744.